Unanticipated Roadblocks In Ovarian Cancer Drug Development

By Andrew Zupnick, PhD

Ovarian cancer drug development is frequently hindered by treating the disease as a generic solid tumor, a strategy that often fails to account for high levels of disease heterogeneity and treatment resistance. To prevent avoidable delays, study teams must move beyond standardized templates and align eligibility, endpoints, and assessments specifically to the setting of the patient population. Success requires pre-mapping intricate surgical and pathology dependencies, such as biopsy adequacy and tissue routing, to ensure screening windows reflect the reality of clinical workflows rather than idealized timelines. Additionally, establishing enabled referral pipelines from community centers to gynecologic oncologists is essential for capturing pre-screening opportunities that are otherwise lost. By selecting countries based on site-level surgical throughput and biomarker access rather than macro-level prevalence, sponsors can strengthen trial design to start fast and scale seamlessly. Connect with oncology experts today to identify and address these roadblocks before your timelines slip.